Leveraging the AI-informed AbiLeap™ Platform to Discover Precision pH Sensing T Cell Engagers

• T-cell engagers (TCE) have long held promise for the treatment of solid tumours
• However, most TCEs are limited by on target off tumour activity and associated safety liabilities
• By leveraging the AbiLeap™ platform, Ability Biotherapeutics has developed pH sensing TCEs, active in the low pH microenvironment of the tumour but not in the periphery, providing an avenue for developing precision targeted TCE therapeutics

Speakers:

Patti Giblin

Chief Scientific Officer

Ability Biologics